Those are some of the short positions highlighted in new research from Goldman Sachs, which put together a "Very Important Short Position List." Goldman analyzed 860 hedge-fund portfolios with $1.8 trillion of gross equity positions …
has sent its shareholders on quite the ride this year. The cancer-drug company’s stock was down on its luck back in February, when the shares got caught up in a sweeping selloff in the biotech sector. The stock fell as low as $26.41 on …